Oscotec Inc - Asset Resilience Ratio
Oscotec Inc (039200) has an Asset Resilience Ratio of 61.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Oscotec Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Oscotec Inc's Asset Resilience Ratio has changed over time. See 039200 book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Oscotec Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 039200 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩94.02 Billion | 61.0% |
| Total Liquid Assets | ₩94.02 Billion | 61.00% |
Asset Resilience Insights
- Very High Liquidity: Oscotec Inc maintains exceptional liquid asset reserves at 61.00% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Oscotec Inc Industry Peers by Asset Resilience Ratio
Compare Oscotec Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
KPX Lifescience.Co.Ltd
KQ:114450 |
Pharmaceuticals | 7.59% |
|
GeneBioTech Co. Ltd
KQ:086060 |
Pharmaceuticals | 15.42% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
Caregen Co.Ltd
KQ:214370 |
Pharmaceuticals | 4.58% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 13.09% |
|
Huons Global Co. Ltd
KQ:084110 |
Pharmaceuticals | 5.46% |
Annual Asset Resilience Ratio for Oscotec Inc (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Oscotec Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 52.48% | ₩89.62 Billion ≈ $60.74 Million |
₩170.78 Billion ≈ $115.73 Million |
-21.05pp |
| 2023-12-31 | 73.53% | ₩97.48 Billion ≈ $66.06 Million |
₩132.58 Billion ≈ $89.85 Million |
+1.38pp |
| 2022-12-31 | 72.14% | ₩103.70 Billion ≈ $70.27 Million |
₩143.74 Billion ≈ $97.41 Million |
+42.36pp |
| 2021-12-31 | 29.78% | ₩14.58 Billion ≈ $9.88 Million |
₩48.97 Billion ≈ $33.18 Million |
-7.04pp |
| 2020-12-31 | 36.83% | ₩28.13 Billion ≈ $19.06 Million |
₩76.39 Billion ≈ $51.77 Million |
-36.00pp |
| 2019-12-31 | 72.82% | ₩52.72 Billion ≈ $35.73 Million |
₩72.39 Billion ≈ $49.06 Million |
+22.07pp |
| 2018-12-31 | 50.75% | ₩35.66 Billion ≈ $24.17 Million |
₩70.26 Billion ≈ $47.61 Million |
-7.86pp |
| 2017-12-31 | 58.62% | ₩23.77 Billion ≈ $16.11 Million |
₩40.54 Billion ≈ $27.48 Million |
+34.77pp |
| 2016-12-31 | 23.84% | ₩9.73 Billion ≈ $6.59 Million |
₩40.81 Billion ≈ $27.66 Million |
-2.28pp |
| 2015-12-31 | 26.12% | ₩12.93 Billion ≈ $8.76 Million |
₩49.50 Billion ≈ $33.54 Million |
+9.67pp |
| 2014-12-31 | 16.45% | ₩5.97 Billion ≈ $4.04 Million |
₩36.27 Billion ≈ $24.58 Million |
-3.15pp |
| 2013-12-31 | 19.61% | ₩7.38 Billion ≈ $5.00 Million |
₩37.65 Billion ≈ $25.51 Million |
-6.59pp |
| 2012-12-31 | 26.19% | ₩11.28 Billion ≈ $7.64 Million |
₩43.05 Billion ≈ $29.17 Million |
+14.28pp |
| 2011-12-31 | 11.91% | ₩5.72 Billion ≈ $3.87 Million |
₩47.98 Billion ≈ $32.51 Million |
-- |
About Oscotec Inc
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody… Read more